Form 4: Dyne Therapeutics CCO Sells Shares for Tax Obligations

Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, sold 144 shares of common stock at a weighted average price of $20.72 to cover tax withholding obligations related to RSU vesting.

Summary

• Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc. (DYN), reported a transaction on December 5, 2025.
• The transaction involved the sale of 144 shares of Dyne Therapeutics common stock.
• The shares were sold at a weighted average price of $20.72 per share, with individual sales ranging from $20.58 to $20.96.
• This sale was automatic and non-discretionary, executed to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) granted on December 4, 2024.
• The sale was conducted under a Rule 10b5-1 plan, indicating it was a pre-arranged transaction.
• Following this transaction, Johanna Friedl-Naderer beneficially owns 94,729 shares of common stock, which includes 72,152 unvested RSUs.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax purposes, not indicative of management's sentiment towards the company's future performance or a strategic move.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Industry Context

This transaction is a routine insider compensation event, specifically a tax-related sale following RSU vesting. It does not provide direct insights into broader industry trends or competitive positioning, but reflects standard executive compensation practices involving equity awards within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: A minor, non-discretionary reduction in direct insider ownership, which is a common occurrence and generally has minimal impact on investor sentiment or share price.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. This type of insider transaction is not typically indicative of management's view on the company's future prospects and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

Dyne Therapeutics, DYN, Form 4, insider transaction, stock sale, RSU vesting, tax withholding, Johanna Friedl-Naderer, Chief Commercial Officer